NeoZanHER, a phase 2 trial, reported early-stage activity for zanidatamab in patients with HER2-positive breast cancer treated before surgery. Presented as the first look at a preoperative strategy using a next-generation antibody designed to engage the HER2 receptor through two distinct mechanisms, the study evaluates the approach in a window where pathological response can guide future development. Published in Nature Communications in 2026, the trial was led by the study team in its NeoZanHER phase 2 cohort and focuses on the disease biology of HER2-driven tumors in the neoadjuvant setting. The pre-surgical model is often used to test whether immune and tumor-directed pharmacology translates into measurable tumor reduction. For pipeline decision-making, the key question is whether the regimen can deliver robust response signals that support progression into larger registration efforts and broader HER2-positive subgroups.